Altria's Investment in Juul Valued at $450 Million

Aug.02.2022
Altria's Investment in Juul Valued at $450 Million
Altria's 35% stake in Juul, the leading e-cigarette manufacturer, has decreased in value by 95% due to increasing safety concerns.

Juul became the global leader in electronic cigarette manufacturing in 2018, with its products gaining widespread popularity. Virginia-based tobacco brand Altria did not want to miss out on the opportunity presented by the rapidly growing e-cigarette market and acquired a 35% stake in Juul for 12.8% of the price. At the time, Altria firmly believed that e-cigarettes represented the future of tobacco use worldwide, and Juul was leading the way towards this promising future.


However, the reality is quite different. Recently, reports claiming that electronic cigarettes are just as dangerous as traditional smoking have dampened enthusiasm for the market, sending shockwaves throughout the entire industry. Even Juul, once the world's most valuable e-cigarette company, has seen its valuation drop following concerns raised by the FDA about the safety of its products, despite a recent investment from Altria.


Tobacco company Altria's investment in Juul is now valued at $450 million, less than 5% of the e-cigarette maker's 2018 valuation. Earlier this year, Altria lowered its valuation of Juul to $1.6 billion as the US Food and Drug Administration began reviewing Juul's products. In its Q2 earnings report, Altria further reduced the valuation by $1.2 billion, putting the new value at $450 million. Despite the drastic reduction, Altria says it has no plans to work with Juul and will honor its original agreement not to launch any new e-cigarette products or invest in other e-cigarette companies. "We made the decision not to make any different decisions," said Altria CEO Billy Gifford. "We believe the right decision at this point in time is to maintain noncompetition.


The rapid decline in Juul's valuation is due to the FDA's decision last month to ban Juul e-cigarettes, as the company failed to provide key information about its nicotine formula. This surprised many as the FDA has approved many similar products. While Juul received criticism from a federal court to continue selling its products, the FDA has re-examined the company's application and frozen its ban. This means that the future of Juul's products remains uncertain in the foreseeable future.


The FDA's decision stems from recent studies that indicate e-cigarettes are harmful to users and pressure from advocacy groups who believe these products are just as bad as traditional tobacco products. Therefore, the FDA is working to eliminate products that do not help smokers quit. Juul's various flavors and brightly colored packaging are attractive to non-smokers. Aside from its valuation, Juul's current issues have also led to a nearly 60% decrease in Altria's earnings to 49 cents per share. This has caused a 6% decrease in quarterly revenue to around $6.5 billion. Altria is the largest cigarette manufacturer in the US and, as smoking rates decline, the company is fighting hard in the Juul and future e-cigarette market.


This article is compiled from third-party information and is only for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot verify the truthfulness or accuracy of the content. The translation of this article is intended for industry-related discussions and research purposes only.


Due to limitations in translation capabilities, the translated article may not express the original meaning accurately. Please refer to the original article for accuracy.


2FIRSTS aligns completely with the Chinese government's views and positions on all domestic, Hong Kong, Macau, Taiwan, and international matters.


The compilation of information belongs to the original media outlet and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Philip Morris International (PMI) introduced TEREA Bold Red and Bold Black heated tobacco sticks in Germany in October 2026, both carrying a brand-rated tobacco-flavor intensity of 10, the highest level in the country's TEREA portfolio. Bold Red features leather and warm woody notes, while Bold Black combines woody and subtle floral notes. Both are sold in 20-stick packs at €8, approximately 2.6% above standard TEREA products. Germany's TEREA range now includes 11 flavor variants, alongside a separate 26-stick XL format priced at €10. IQOS Germany announced the new products on October 12, followed by a phased retail rollout from late October and an IQOS Club campaign running through December.
product
Nov.02
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italy's Guardia di Finanza announced on October 28 that officers in Latina province had seized approximately 4.3 million e-cigarettes and smoking accessories at an unauthorized warehouse in an operation involving restrictions on the possession and sale of tobacco-related products. Another 300,000 suspected counterfeit or unsafe items were confiscated during separate inspections, bringing total seizures across the operations to more than 4.6 million products. Twenty-eight people were reported to judicial authorities over suspected smuggling and counterfeiting offenses. Officials did not disclose separate vape quantities, the value of the merchandise or alleged violations associated with individual brands.
Enforcement
Oct.29
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12